Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aloxiprin, also known as aluminium acetylsalicylate, is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain and inflammation associated with musculoskeletal and joint disorders. It is a chemical compound formed from aluminium hydroxide and aspirin (acetylsalicylic acid). Aloxiprin acts as an anti-inflammatory, antipyretic, analgesic, and antiplatelet agent. Its mechanism of action involves inhibition of cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) enzymes, leading to reduced synthesis of prostaglandins and thromboxanes—key mediators in inflammation and pain pathways. This results in decreased inflammation, fever reduction, pain relief, and inhibition of platelet aggregation[1][3][6][8]. Aloxiprin may be preferred over aspirin alone due to potentially improved gastrointestinal tolerability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aloxiprin.